ArticleJournal of thoracic disease2026
Prognostic role of hemoglobin, albumin, lymphocyte and platelet score in esophageal cancer: a systematic review and meta-analysis.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The association of hemoglobin, albumin, lymphocyte and platelet (HALP) score with clinical outcomes in esophageal cancer patients remains unclear. A comprehensive and systematic review and meta-analysis are needed to investigate on this topic. Methods: PubMed, Web of Science and Chinese National Knowledge Infrastructure (CNKI) databases were searched up to December 7, 2025. Primary prognostic indicator included the overall survival (OS), progression-free survival (PFS), disease-free survival (DFS) and cancer-specific survival (CSS). Secondary prognostic indicators consisted of the therapeutic effect including the major pathological response (MPR), objective response rate (ORR) and complete response rate (CRR) and risk of postoperative complications. Results: Eleven studies were included. Pooled results demonstrated that lower HALP score was related to poorer OS [hazard ratio (HR) =1.76, 95% confidence interval (CI): 1.34-2.31, P<0.001], DFS (HR =1.61, 95% CI: 1.03-2.53, P=0.04) and CSS (HR =2.023, 95% CI: 1.549-2.644, P<0.001), as well as the PFS (HR =1.54, 95% CI: 0.98-2.41, P=0.06). Besides, lower HALP score was associated with significantly better MPR [odds ratio (OR) =0.335, 95% CI: 0.125-0.807, P=0.02] and ORR (OR =0.443, 95% CI: 0.234-0.841, P=0.006), indicating inferior treatment response. No significant association between HALP score and risk of postoperative complications was observed. Conclusions: HALP score was associated with the survival and therapeutic effect of anti-tumor treatment and lower HALP might indicate worse prognosis in esophageal cancer patients. More high-quality studies are needed to further identify above findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.